Rawla Prashanth, Sunkara Tagore, Ofosu Andrew, Gaduputi Vinaya
Department of Internal Medicine, SOVAH Health, Martinsville, VA 24112, United States.
Division of Gastroenterology and Hepatology, The Brooklyn Hospital Center, Clinical Affiliate of The Mount Sinai Hospital, New York, NY 11201, United States.
World J Gastrointest Pharmacol Ther. 2018 Dec 13;9(7):63-68. doi: 10.4292/wjgpt.v9.i7.63.
The modern lifestyle caters to an increase in the incidence of peptic ulcer disease, gastroesophageal reflux disease and several other acid-related conditions of the gut. The drugs to prevent these conditions work either through H2 receptor blockade or inhibition of the H, K ATPase enzyme. Although proton pump inhibitors have been proven to be efficacious, they have a slow onset of action with limited resolution of symptoms in most patients. Potassium-competitive acid blockers (P-CABs) are novel drugs that bind reversibly to K ions and block the H, K ATPase enzyme, thus preventing acid production. P-CABs have a fast onset of action and have dose-dependent effects on acid production. Animal studies exist that differentiate the better results of P-CABs from proton pump inhibitors; further human trials will give a comprehensive picture of the results and will help to elucidate the therapeutic benefits of this new group of drugs.
现代生活方式导致消化性溃疡病、胃食管反流病以及其他几种肠道酸相关疾病的发病率上升。预防这些疾病的药物要么通过H2受体阻断起作用，要么通过抑制H、K ATP酶起作用。尽管质子泵抑制剂已被证明有效，但它们起效缓慢，大多数患者症状缓解有限。钾竞争性酸阻滞剂（P-CABs）是一类新型药物，可与钾离子可逆性结合，阻断H、K ATP酶，从而阻止胃酸分泌。P-CABs起效迅速，对胃酸分泌有剂量依赖性作用。已有动物研究区分了P-CABs与质子泵抑制剂的更佳效果；进一步的人体试验将全面呈现结果，并有助于阐明这类新药物的治疗益处。
